You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,609,095

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,609,095

Title:	Anti-HER2 antibodies and compositions
Abstract:	The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
Inventor(s):	Pedersen; Mikkel Wandahl (Alleroed, DK), Jensen; Allan (Aberdeen, GB), Meijer; Per-Johan (Lyngby, DK)
Assignee:	Symphogen A/S (Lyngby, DK)
Application Number:	13/040,029
Patent Claims:	1. An antibody composition comprising a first recombinant anti-HER2 antibody that comprises the CDR1, CDR2 and CDR3 of the heavy chain variable region in SEQ ID NO: 2 and the CDR1, CDR2 and CDR3 of the light chain variable region in SEQ ID NO: 4; and a second recombinant anti-HER2 antibody that comprises the CDR1, CDR2 and CDR3 of the heavy chain variable region in SEQ ID NO: 22 and the CDR1, CDR2 and CDR3 of the light chain variable region in SEQ ID NO: 24. 2. An antibody composition comprising at least first and second recombinant anti-HER2 antibodies that bind distinct epitopes of HER2, wherein each of said first and second antibodies binds to the same epitope as and competes for binding with the following antibodies, respectively: a) an anti-HER2 antibody that comprises the CDR1, CDR2 and CDR3 of the heavy chain variable region in SEQ ID NO: 2 and the CDR1, CDR2 and CDR3 of the light chain variable region in SEQ ID NO: 4; and b) an anti-HER2 antibody that comprises the CDR1, CDR2 and CDR3 of the heavy chain variable region in SEQ ID NO: 22 and the CDR1, CDR2 and CDR3 of the light chain variable region in SEQ ID NO: 24. 3. The antibody composition of claim 1 or 2, wherein at least one recombinant anti-HER2 antibody in said composition is an immunoconjugate comprising a recombinant anti-HER2 antibody conjugated to an anti-cancer agent. 4. The antibody composition of claim 3, wherein the anti-cancer agent is selected from the group consisting of cytotoxic agents, cytokines, toxins and radionuclides. 5. The antibody composition of claim 1, wherein the first recombinant anti-HER2 antibody comprises the heavy chain variable region in SEQ ID NO: 2 and the light chain variable region in SEQ ID NO: 4; and the second recombinant anti-HER2 antibody comprises the heavy chain variable region in SEQ ID NO: 22 and the light chain variable region in SEQ ID NO: 24. 6. The antibody composition of claim 1, wherein the first or the second recombinant anti-HER2 antibody, or both, are an IgG isotype. 7. The antibody composition of claim 1 or 2, wherein the first or the second recombinant anti-HER2 antibody, or both, are humanized. 8. A method for treating cancer in a human or other mammal, the method comprising administering to said mammal an recombinant anti-HER2 antibody composition according to claim 1 or 2. 9. A method for treating a patient with a disorder characterized by overexpression of HER2, the method comprising administering to said patient an anti-HER2 antibody composition according to claim 1 or 2. 10. A method for reducing heterodimer formation between HER2 and other ErbB family receptors in cells that overexpress HER2, the method comprising contacting said cells with an anti-HER2 antibody composition according to claim 1 or 2. 11. A method for inducing internalization of HER2 on the surface of cells that overexpress HER2, the method comprising contacting the cells with an anti-HER2 antibody composition according to claim 1 or 2. 12. A method for inhibiting growth of tumor cells that are resistant or partially resistant to treatment with a recombinant anti-HER2 antibody, the method comprising contacting the cells with an anti-HER2 antibody composition according to claim 1 or 2. 13. The method of claim 12, where the tumor cells have been previously treated with trastuzumab.

Details for Patent 8,609,095

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2030-03-04
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2030-03-04
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2030-03-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.